BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37669902)

  • 1. The reliability and validity of lung cancer and melanoma clinical quality survival measures.
    Pendl-Robinson E; Calkins KL; Simon SE; Barrett K; Poznyak D
    Health Serv Res; 2023 Oct; 58(5):1131-1140. PubMed ID: 37669902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Reliability and Correlations of Quality Measures in Cancer Care.
    Keating NL; Cleveland JLF; Wright AA; Brooks GA; Meneades L; Riedel L; Zubizarreta JR; Landrum MB
    JAMA Netw Open; 2021 Mar; 4(3):e212474. PubMed ID: 33749769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis.
    Owonikoko TK; Ragin C; Chen Z; Kim S; Behera M; Brandes JC; Saba NF; Pentz R; Ramalingam SS; Khuri FR
    Oncologist; 2013; 18(5):600-10. PubMed ID: 23635558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer.
    Huang L; Feng Y; Xie T; Zhu H; Tang L; Shi Y
    BMC Cancer; 2023 Apr; 23(1):312. PubMed ID: 37020179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer.
    West H; Hu X; Zhang S; Song Y; Chirovsky D; Gao C; Lerner A; Jiang A; Signorovitch J; Samkari A
    J Manag Care Spec Pharm; 2023 Jul; 29(7):749-757. PubMed ID: 37404067
    [No Abstract]   [Full Text] [Related]  

  • 6. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
    Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
    Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US.
    Ganti AK; Klein AB; Cotarla I; Seal B; Chou E
    JAMA Oncol; 2021 Dec; 7(12):1824-1832. PubMed ID: 34673888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study.
    Kinslow CJ; May MS; Saqi A; Shu CA; Chaudhary KR; Wang TJC; Cheng SK
    Clin Lung Cancer; 2020 Mar; 21(2):e99-e113. PubMed ID: 31601526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.
    Zhu J; Sharma DB; Gray SW; Chen AB; Weeks JC; Schrag D
    JAMA; 2012 Apr; 307(15):1593-601. PubMed ID: 22511687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
    Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis.
    Kravchenko J; Berry M; Arbeev K; Lyerly HK; Yashin A; Akushevich I
    Lung Cancer; 2015 Apr; 88(1):85-93. PubMed ID: 25704956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
    Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.
    Deepak JA; Ng X; Feliciano J; Mao L; Davidoff AJ
    Ann Am Thorac Soc; 2015 May; 12(5):742-51. PubMed ID: 25760983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data.
    Goncalves PH; Peterson SL; Vigneau FD; Shore RD; Quarshie WO; Islam K; Schwartz AG; Wozniak AJ; Gadgeel SM
    Cancer; 2016 Jun; 122(12):1921-7. PubMed ID: 27062154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
    Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
    J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Diagnostic Delays on Lung Cancer Survival Outcomes: A Population Study of the US SEER-Medicare Database.
    Romine PE; Sun Q; Fedorenko C; Li L; Tang M; Eaton KD; Goulart BHL; Martins RG
    JCO Oncol Pract; 2022 Jun; 18(6):e877-e885. PubMed ID: 35119911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological analysis of progression-free survival (PFS) and overall survival (OS) in non-small-cell lung cancer patients in Republic of Macedonia.
    Risteski M; Crvenkova S; Atanasov Z; Isjanovska R
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2013; 34(3):49-61. PubMed ID: 24566015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The characteristics and survival of second primary lung cancer after Hodgkin's lymphoma: A comparison with first primary lung cancer using the SEER database.
    Lin L; Wang D; Chen H
    PLoS One; 2023; 18(5):e0285766. PubMed ID: 37195975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival associated with chronic obstructive pulmonary disease among SEER-Medicare beneficiaries with non-small-cell lung cancer.
    Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():893-903. PubMed ID: 31118599
    [No Abstract]   [Full Text] [Related]  

  • 20. The Effect of Advances in Lung-Cancer Treatment on Population Mortality.
    Howlader N; Forjaz G; Mooradian MJ; Meza R; Kong CY; Cronin KA; Mariotto AB; Lowy DR; Feuer EJ
    N Engl J Med; 2020 Aug; 383(7):640-649. PubMed ID: 32786189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.